Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
article
OA: gold
CC0
⤵ 3 in-corpus citations
AI-generated summary
This review summarizes the key clinical studies that led to the regulatory approval of elagolix, the first oral gonadotropin-releasing hormone antagonist, for endometriosis and uterine fibroids.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist 2017
- Long-Term Outcomes of Elagolix in Women With Endometriosis 2018
- Clinical Evaluation of the Oral Gonadotropin-Releasing Hormone-Antagonist Elagolix for the Management of Endometriosis-Associated Pain 2019
- Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain 2018
Cited by (3)
- Computational drug repurposing effort for identifying novel hits for the treatment of diseases such as endometriosis, uterine fibroids, and prostate cancer 2024
- The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study 2024
- Abnormal uterine bleeding: The well-known and the hidden face 2024
References (12)
- Clinical Evaluation of the Oral Gonadotropin-Releasing Hormone-Antagonist Elagolix for the Management of Endometriosis-Associated Pain via openalex
- Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain via openalex
- Long-Term Outcomes of Elagolix in Women With Endometriosis via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
- W2610244466 via openalex
- W2896492055 via openalex
- W3002354512 via openalex
- W2076668848 via openalex
- W3022548192 via openalex
- W2085320423 via openalex
- W2145060895 via openalex
- W2195249017 via openalex
Cited by (3)
- Computational drug repurposing effort for identifying novel hits for the treatment of diseases such as endometriosis, uterine fibroids, and prostate cancer 2024
- Abnormal uterine bleeding: The well-known and the hidden face 2024
- The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study 2024
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-06-04T00:33:50.911596+00:00
License: CC0
· commercial use OK